Rhythm in step with hot biotech IPO market

摘要

Biotech IPOs remain a consistent source of outperformance. The nine IPOs that were priced in the third quarter have produced an average aftermarket return of 55%, easily beating the benchmark Nasdaq Biotechnology Index's 9.7% gain since June 30. It is no surprise that biotech IPOs have just kept coming.